Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Neurobiology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for PTPRD drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PTPRD ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View PTPRD Products |
| Gene Delivery | PTPRD Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View PTPRD Products |
| Benchmark Ab | Anti-PTPRD Recombinant Antibody Recombinant positive control for assay validation. |
View PTPRD Products |
| Validator | PTPRD siRNA Set For knockdown verification in functional assays. |
View PTPRD Products |
| Related Target A | STAT3 Downstream transcription factor directly dephosphorylated by PTPRD; key node in oncology pathways. |
View STAT3 Products |
| Related Target B | IL1RAPL1 Trans-synaptic binding partner of PTPRD; essential for synaptic adhesion and neurodevelopmental assays. |
View IL1RAPL1 Products |
| Related Target C | PTPRS Subfamily homolog (PTPσ); critical for counter-screening to ensure drug selectivity. |
View PTPRS Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Maintaining native conformation of the large extracellular domain | HEK293 expressed recombinant ECD-Fc with native glycosylation patterns |
| Subfamily counter-screening (PTPRF/PTPRS cross-reactivity) | Homolog panel proteins strictly verified by mass spectrometry and high purity (>95%) |
| Lack of Controls | Sequence-verified clinical benchmark antibodies included |
| False Positives | Validated siRNA sets included for target specificity checks |
Live PTPRD R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of Receptor-type tyrosine-protein phosphatase delta (PTPRD) represents a highly specialized frontier spanning oncology and neuropsychiatry. Historically classified as a tumor suppressor frequently mutated or deleted in glioblastoma, lung cancer, and cutaneous squamous cell carcinoma, PTPRD regulates key oncogenic pathways by dephosphorylating STAT3 and Aurora Kinase A. Conversely, in the central nervous system, PTPRD acts as a critical synaptic adhesion molecule regulating excitatory synapse formation.
The race for PTPRD therapeutics is intensifying, with major players shifting focus from traditional mAbs to small-molecule modulators and synaptic-targeting biologics. As first-generation therapies reach the clinic, the next wave of R&D is targeting the precise disruption of PTPRD-synaptic partner interactions or the restoration of PTPRD phosphatase activity in deficient tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Activators | Academic Institutes, Biotech Startups | Glioblastoma, Solid Tumors | Phosphatase Activity Assays (Need highly pure, active intracellular domain proteins) |
| Monoclonal Antibodies | Neuroscience-focused Biopharma | Neurodevelopmental disorders, Synaptic repair | Epitope mapping & binding kinetics (Need HEK293-expressed ECD-Fc proteins) |
| Gene Therapy (Lentivirus/AAV) | Oncology Therapeutics Developers | PTPRD-deficient Cancers | In vitro validation (Need high-titer Lentivirus for stable cell line construction) |